Novavax Inc.’s Covid-19 vaccine candidate showed strong efficacy against the coronavirus, including mutated variants, during a large trial.
Novavax Inc.’s Covid-19 vaccine candidate showed strong efficacy against the coronavirus, including mutated variants, during a large trial.
The shot was 90% effective at preventing symptomatic Covid and 100% effective at preventing moderate and severe symptoms, the U.S. biotech firm said Monday. The shot was 93% effective against variants of concern, it said.
“Novavax is one step closer to addressing the critical and protracted global public health need for extra Covid-19 vaccines,” Chief military officer Stanley C. Erck said during a statement.
“Novavax continues to figure with a way of urgency to finish our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that's still in great need of vaccines.”
Novavax shares rose 8.5% in premarket U.S. trading.
The company previously said it wouldn’t file for vaccine authorization within the U.S. and Europe until the third quarter of the year. Novavax says it’s on target to succeed in manufacturing capacity of 100 million doses per month by the top of the third quarter and 150 million per month by the top of 2021.
The company’s phase 3 trial included almost 30,000 participants within the U.S. and Mexico.
